Renaissance Technologies
IKT icon

Renaissance Technologies’s Inhibikase Therapeutics IKT Stock Holding History

Renaissance Technologies’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,500
Closed -$27.7K – 3403
2026
Q1 		$27.7K Buy
+16,500
New +$29.3K ﹤0.01% 3153
2024
Q4 		– Sell
-19,922
Closed -$25.9K – 3725
2024
Q3 		$25.9K Sell
19,922
-900
-4% -$1.21K ﹤0.01% 3414
2024
Q2 		$25.2K Sell
20,822
-600
-3% -$1.03K ﹤0.01% 3362
2024
Q1 		$46K Sell
21,422
-3,000
-12% -$6.62K ﹤0.01% 3496
2023
Q4 		$31K Buy
24,422
+8,300
+51% +$8.59K ﹤0.01% 3526
2023
Q3 		$22K Buy
16,122
+3,400
+27% +$7.62K ﹤0.01% 3515
2023
Q2 		$46K Buy
12,722
+1,505
+13% +$5.61K ﹤0.01% 3631
2023
Q1 		$44K Buy
11,217
+2,550
+29% +$10.6K ﹤0.01% 3687
2022
Q4 		$26K Sell
8,667
-12,114
-58% -$48K ﹤0.01% 3914
2022
Q3 		$113K Sell
20,781
-16,202
-44% -$85.3K ﹤0.01% 3552
2022
Q2 		$165K Buy
36,983
+5,571
+18% +$32.9K ﹤0.01% 3717
2022
Q1 		$279K Sell
31,412
-2,121
-6% -$17.1K ﹤0.01% 3501
2021
Q4 		$296K Buy
+33,533
New +$370K ﹤0.01% 3348

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies's IKT Position: Q2 2026 in Review

Renaissance Technologies sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 16,500 shares — an estimated $27.7K sold.

Renaissance Technologies first reported a position in IKT in Q4 2021 and held it in 13 quarters. The position peaked at $296K in Q4 2021. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Renaissance Technologies reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 16,500 Inhibikase Therapeutics shares in Q2 2026, an estimated $27.7K.
  • Renaissance Technologies first reported a position in Inhibikase Therapeutics in Q4 2021 and held it in 13 quarters.
  • Renaissance Technologies's Inhibikase Therapeutics position peaked at $296K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.